Your browser doesn't support javascript.
loading
The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial.
Nordlund, Julia; Henry, Richard S; Kwakkenbos, Linda; Carrier, Marie-Eve; Levis, Brooke; Nielson, Warren R; Bartlett, Susan J; Dyas, Laura; Tao, Lydia; Fedoruk, Claire; Nielsen, Karen; Hudson, Marie; Pope, Janet; Frech, Tracy; Gholizadeh, Shadi; Johnson, Sindhu R; Piotrowski, Pamela; Jewett, Lisa R; Gordon, Jessica; Chung, Lorinda; Bilsker, Dan; Levis, Alexander W; Turner, Kimberly A; Cumin, Julie; Welling, Joep; Fortuné, Catherine; Leite, Catarina; Gottesman, Karen; Sauve, Maureen; Rodríguez-Reyna, Tatiana Sofía; Larche, Maggie; van Breda, Ward; Suarez-Almazor, Maria E; Wurz, Amanda; Culos-Reed, Nicole; Malcarne, Vanessa L; Mayes, Maureen D; Boutron, Isabelle; Mouthon, Luc; Benedetti, Andrea; Thombs, Brett D.
Afiliação
  • Nordlund J; Lady Davis Institute of the Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montreal, Quebec, H3T 1E2, Canada.
  • Henry RS; Lady Davis Institute of the Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montreal, Quebec, H3T 1E2, Canada.
  • Kwakkenbos L; Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
  • Carrier ME; Department of Clinical Psychology, Radboud University, Nijmegen, The Netherlands.
  • Levis B; Department of Medical Psychology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Nielson WR; Lady Davis Institute of the Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montreal, Quebec, H3T 1E2, Canada.
  • Bartlett SJ; Centre for Prognosis Research, School of Medicine, Keele University, Keele, Staffordshire, UK.
  • Dyas L; St. Joseph's Health Care, London, Ontario, Canada.
  • Tao L; Department of Medicine, McGill University, Montreal, Quebec, Canada.
  • Fedoruk C; Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
  • Nielsen K; Scleroderma Foundation, Michigan Chapter, Southfield, MI, USA.
  • Hudson M; Lady Davis Institute of the Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montreal, Quebec, H3T 1E2, Canada.
  • Pope J; Lady Davis Institute of the Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montreal, Quebec, H3T 1E2, Canada.
  • Frech T; Scleroderma Society of Ontario, Hamilton, Ontario, Canada.
  • Gholizadeh S; Lady Davis Institute of the Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montreal, Quebec, H3T 1E2, Canada.
  • Johnson SR; Department of Medicine, McGill University, Montreal, Quebec, Canada.
  • Piotrowski P; Department of Medicine, University of Western Ontario, London, Ontario, Canada.
  • Jewett LR; Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
  • Gordon J; California School of Professional Psychology/Alliant, Los Angeles, CA, USA.
  • Chung L; Toronto Scleroderma Program, Mount Sinai Hospital & Toronto Western Hospital, Toronto, Ontario, Canada.
  • Bilsker D; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.
  • Levis AW; Private practice - Nutrition, Milton, Ontario, Canada.
  • Turner KA; Department of Psychology, Jewish General Hospital, Montreal, Quebec, Canada.
  • Cumin J; Department of Medicine, Hospital for Special Surgery, New York City, NY, USA.
  • Welling J; Department of Medicine, Stanford University, Palo Alto, CA, USA.
  • Fortuné C; Department of Medicine, Palo Alto VA Health Care System, Palo Alto, CA, USA.
  • Leite C; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
  • Gottesman K; Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
  • Sauve M; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
  • Rodríguez-Reyna TS; Lady Davis Institute of the Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montreal, Quebec, H3T 1E2, Canada.
  • Larche M; Lady Davis Institute of the Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montreal, Quebec, H3T 1E2, Canada.
  • van Breda W; NVLE Dutch patient organization for systemic autoimmune diseases, Utrecht, The Netherlands.
  • Suarez-Almazor ME; Ottawa Scleroderma Support Group, Ottawa, Ontario, Canada.
  • Wurz A; University of Minho, Braga, Portugal.
  • Culos-Reed N; Scleroderma Foundation, Los Angeles, CA, USA.
  • Malcarne VL; Scleroderma Society of Ontario, Hamilton, Ontario, Canada.
  • Mayes MD; Scleroderma Canada, Hamilton, Ontario, Canada.
  • Boutron I; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Mouthon L; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
  • Benedetti A; Faculty of Behavioural and Movement Sciences, VU University, Amsterdam, The Netherlands.
  • Thombs BD; Department of General Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Trials ; 22(1): 856, 2021 Nov 27.
Article em En | MEDLINE | ID: mdl-34838105

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 11_ODS3_cobertura_universal / 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Escleroderma Sistêmico / Autogestão / COVID-19 Tipo de estudo: Clinical_trials Aspecto: Implementation_research Limite: Humans Idioma: En Revista: Trials Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 11_ODS3_cobertura_universal / 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Escleroderma Sistêmico / Autogestão / COVID-19 Tipo de estudo: Clinical_trials Aspecto: Implementation_research Limite: Humans Idioma: En Revista: Trials Ano de publicação: 2021 Tipo de documento: Article